Interleukin 15, Recombinant, Mouse (IL-15)

Interleukin (IL)-15 is a pleiotropic pro-inflammatory cytokine that is expressed in several inflammatory disorders, including rheumatoid arthritis, psoriasis and pulmonary inflammatory diseases. IL-15 promotes activation of T cells, neutrophils and macrophages, and is critical to dendritic cell function in several model systems. Recent emerging data suggest that IL-15 may serve as a useful therapeutic target across a range of disease states. Advances in the past year highlight the beneficial effect of IL-15 neutralisation in models of psoriasis and diabetes. Further evidence for IL-15 expression and effector function has emerged across a range of rheumatic disorders, including juvenile inflammatory arthritis, rheumatoid arthritis and Kawasaki disease. Interleukin-15 (IL-15) is a gamma-common cytokine, which plays an important role in the development, survival and proliferation of NK, NK T and CD8+ T cells. \n\nBiological Activity: murine IL-15 is fully biologically active when compared to standard. The ED50 as determined by the dose-dependent stimulation of the proliferation of mouse CTLL-2 was found to be < 5ng/ml, corresponding to a Specific Activity of 2x105IU/mg.\n\nAA Sequence:\nMNWIDVRYDL EKIESLIQSI HIDTTLYTDS DFHPSCKVTA MNCFLLELQV ILHEYSNMTL NETVRNVLYL ANSTLSSNKN VAESGCKECE ELEEKTFTEF LQSFIRIVQM FINTS \n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O, aliquot and store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I8437-05C

Size

2ug

Form

Supplied as a lyophilized powder. Reconstitute with sterile dH2O PBS to 0.1-1mg/ml, which can be further diluted into other aqueous solutions.

Purity

(same/more than) 95% as determined by RP-HPLC; Reducing and non-reducing SDS-PAGE.

References

1. Juxtacrine function of interleukin-15/interleukin-15 receptor system in tumour derived human B-cell lines. Clin Exp Immunol 2006 Dec;146(3):559-66\n2. Interleukin-15 increases glucose uptake in skeletal muscle. An antidiabetogenic effect of the cytokine. Biochim Biophys Acta 2006 Nov;1760(11):1613-7\n3. Prolonged exposure of naive CD8+ T cells to interleukin-7 or interleukin-15 stimulates proliferation without differentiation or loss of telomere length. Immunology 2006 Oct;119(2):243-53\n4. Docking of human interleukin-15 to its specific receptor alpha chain: correlation between molecular modeling and mutagenesis experimental data. Proteins 2006 Nov 15;65(3):623-36\n5. Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. Acta Trop 2006 Aug;99(1):83-7\n6. Decreased peritoneal concentrations of interleukin-15 in women with advanced stage endometriosis. Eur J Obstet Gynecol Reprod Biol 2006 Dec;129(2):169-73